Multiple Tumor Types TAPUR

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

Eligibility Criteria:

  • Patient with a histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma
  • No longer benefitting from standard anti-cancer treatment
  • Disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma)
  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression

This study is for patients age 18 and older.

Available at: Hartford Hospital, Hospital of Central Connecticut, Midstate Medical Center, William Backus Hospital, Windham Hospital, Charlotte Hungerford Hospital, St. Vincent's Medical Center.

Click here to view the clinicaltrials.gov listing for this trial.

Cancer Clinical Research Office